Status:
COMPLETED
Study of T3 for the Treatment of Fibromyalgia
Lead Sponsor:
Stanford University
Conditions:
Fibromyalgia
Eligibility:
All Genders
18-50 years
Phase:
NA
Brief Summary
Determine if T3 - the active form of thyroid hormone - is beneficial in fibromyalgia. Determine the feasibility and promise of an appropriately powered future prospective randomized controlled study o...
Eligibility Criteria
Inclusion
- Age 18-50
- Meet american college of rheumatology criteria for fibromyalgia
- at baseline report an average pain of 4 or more on a brief Pain Inventory.
- can climb 2 flights of stairs without shortness of breath.
Exclusion
- new medication change in the last 2 months
- any cardiac disease at all
- known thyroid disease before or after thyroid screening bloodwork
- unstable medical or psychiatric disease.
- Known inflammatory or rheumatic disease other than fibromyalgia
- substance abuse in the last year
- suicidality or depression as indicated by a Beck Depression Inventory of 30 or above
- concomitant herbal medications
- multiple severe medication allergies
- the assessment of the research team that inclusion of the subject could in some way compromise the safety and validity of the study.
- diabetes
- smoking
- Known uncontrolled hypertension
- known uncontrolled hypercholesterolemia
Key Trial Info
Start Date :
May 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2011
Estimated Enrollment :
51 Patients enrolled
Trial Details
Trial ID
NCT00903877
Start Date
May 1 2009
End Date
June 1 2011
Last Update
July 14 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Stanford University School of Medicine
Stanford, California, United States, 94305